Conventional chemotherapy (taxanes, platinum-based agents), EGFR-tyrosine kinase inhibitors (TKIs) [116], and ICIs have improved outcomes in breast [119] and lung cancer but remain constrained by toxicities [120], acquired resistance, and immune-related adverse events (irAEs) [115]. This evidence concerns the gene EGFR and lung carcinoma.